


## About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



## Spherix Provides Independent Expertise in Nine Areas



**Dermatology**



**Nephrology**



**Gastroenterology**



**CNS**



**Rheumatology**



**Ophthalmology**



**Hematology**



**Oncology**

**NEW  
IN 2026!**



**Market Access**

This is a guide to the publications Spherix will produce in 2026. It is organized by therapeutic area, indication, and deliverable.

## Type of Publications

<b>MARKET DYNAMIX</b>	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.
<b>REALTIME DYNAMIX</b>	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.
<b>LAUNCH DYNAMIX</b>	Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
<b>PATIENT CHART DYNAMIX</b>	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmask real patient management patterns and uncovers the "why" behind treatment decisions.
<b>PATIENT VOICE DYNAMIX</b>	An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.
<b>ACCOUNT MANAGEMENT DYNAMIX</b>	Identify best practices to build high-performing national and regional account teams and benchmark your performance against competitors.
<b>BENEFIT DESIGN DYNAMIX</b>	Understand and predict market access trends and policy shifts affecting formulary management and reimbursement across commercial and government channels.
<b>KEY ACCOUNT DYNAMIX</b>	Gain strategic account intelligence on leading national and regional payers, IDNs, and specialty pharmacy accounts to support prioritization, engagement strategy, and planning.
<b>PATIENT SERVICES DYNAMIX</b>	Uncover best practices and comparative intelligence on indication and brand-level patient service programs and competencies.
<b>SPECIAL TOPIX</b>	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.

For a complete index of available reports, visit  
[www.clientportal.spherixglobalinsights.com](http://www.clientportal.spherixglobalinsights.com)

### Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.



## BENEFIT DESIGN DYNAMIX

- Commercial Trends*
  - Market & Stakeholder Landscape
  - Pharmacy Benefits
  - Medical Benefits
  - Employer Trends & Influence
- Government Trends*
  - Market & Stakeholder Landscape
  - Medicare Part D Benefits
  - Medicare Part B Benefits
  - Trends in Medicaid, Exchanges & Other Programs

## KEY ACCOUNT DYNAMIX

- Comparative Assessments*
  - Leading Accounts
  - Blues & Regional Plans
  - Integrated Delivery Networks
  - Specialty Pharmacies
- Account Profiles*
  - Leading Accounts (19 profiles)
  - Blues & Regional Plans (40 profiles)
  - Integrated Delivery Networks (50 profiles)
  - Specialty Pharmacies (14 profiles)

## ACCOUNT MANAGEMENT DYNAMIX

- Payer Benchmarking*
  - Medical Directors
  - Pharmacy Directors
  - Annual Review
- IDN Benchmarking*
  - Medical Directors
  - Pharmacy Directors
  - Annual Review

## PATIENT SERVICES DYNAMIX

- Patient Services Program Benchmarking*
  - Patient Services Best Practices*
- Available in:**
- Autoimmune
  - Oncology
  - Orphan/Rare
  - Women's Health

## SPECIAL TOPIX

- Pathways Influence in Oncology

Key

- BENEFIT DESIGN DYNAMIX** Explore commercial and government payer, physician and employer market experiences
- KEY ACCOUNT DYNAMIX** Reports use detailed data from key decision-makers from leading national payers, regional payers, IDNs and specialty pharmacies.
- ACCOUNT MANAGEMENT DYNAMIX** Reports use extensive data from medical directors and pharmacy directors at payers and IDNs.
- PATIENT SERVICES DYNAMIX** Assesses physician, office staff, patient and caregiver experiences with patient service programs and attributes
- SPECIAL TOPIX** Current events on specific interest areas Current events



## Alopecia Areata

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Alopecia Areata, US</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Leqselvi (SUN Pharma) in Alopecia Areata, US</li> </ul>

## Atopic Dermatitis

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Atopic Dermatitis, JP</li> </ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"> <li>Atopic Dermatitis, US</li> <li>Atopic Dermatitis, EU5</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Ebglyss (Eli Lilly) in Atopic Dermatitis, US</li> <li>Nemluvio (Galderma) in Atopic Dermatitis, US</li> <li>Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US</li> </ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> <li>Atopic Dermatitis, US</li> </ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> <li>Atopic Dermatitis, US</li> <li>Atopic Dermatitis, EU5</li> </ul>

## Chronic Spontaneous Urticaria

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Chronic Spontaneous Urticaria, US</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Dupixent (Sanofi/Regeneron) in CSU, US</li> <li>Rhapsido (Novartis) in CSU, US</li> </ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> <li>Chronic Spontaneous Urticaria, US</li> </ul>

## Hidradenitis Suppurativa

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Hidradenitis Suppurativa, US</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Bimzelx (UCB) in Hidradenitis Suppurativa, US</li> </ul>

## Plaque Psoriasis

REALTIME DYNAMIX	<ul style="list-style-type: none"> <li>Plaque Psoriasis, US</li> <li>Plaque Psoriasis, EU5</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Icotyde (J&amp;J) in Plaque Psoriasis, US</li> </ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> <li>Plaque Psoriasis, US</li> </ul>
SPECIAL TOPIX	<ul style="list-style-type: none"> <li>The Oral Opportunity in Plaque Psoriasis, US</li> </ul>

## Prurigo Nodularis

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Prurigo Nodularis, US</li> </ul>
SPECIAL TOPIX	<ul style="list-style-type: none"> <li>Nemluvio (Galderma) in Prurigo Nodularis, US</li> </ul>

## Other Dermatology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Vitiligo, US</li> </ul>
SPECIAL TOPIX	<ul style="list-style-type: none"> <li>Biologic Coordinators Across Dermatology, US</li> </ul>

## Dermatology-Adjacent Indications

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Asthma, US</li> <li>Asthma, EU</li> <li>Chronic Obstructive Pulmonary Disease, US</li> <li>Chronic Obstructive Pulmonary Disease, EU</li> </ul>
----------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



## Eosinophilic Esophagitis

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Eosinophilic Esophagitis, US</li> </ul>
----------------	--

## Inflammatory Bowel Disease

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Crohn's Disease, JP</li> <li>Ulcerative Colitis, JP</li> </ul>
REALTIME DYNAMIX	<ul style="list-style-type: none"> <li>Crohn's Disease, US</li> <li>Crohn's Disease, EU5</li> <li>Ulcerative Colitis, US</li> <li>Ulcerative Colitis, EU5</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Tremfya (J&amp;J) in Crohn's Disease, US</li> <li>Omvoh (Eli Lilly) in Crohn's Disease, US</li> <li>Tremfya (J&amp;J) in Ulcerative Colitis, US</li> </ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> <li>Inflammatory Bowel Disease New Starts, US</li> <li>Inflammatory Bowel Disease Switching, US</li> <li>Inflammatory Bowel Disease Switching, EU5</li> </ul>
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> <li>Inflammatory Bowel Disease, US</li> </ul>
SPECIAL TOPIX	<ul style="list-style-type: none"> <li>Biologic Coordinators in Gastroenterology, US</li> <li>The Role of APPs in IBD</li> </ul>

## Obesity

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Obesity, US</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Wegovy Pill (Novo Nordisk) in Obesity, US</li> <li>Orforglipron (Eli Lilly) in Obesity, US</li> <li>CagriSema (Novo Nordisk) in Obesity, US</li> </ul>

## MASH

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>MASH, US</li> <li>MASH, EU5</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Rezdiffra (Madrigal) in MASH, US</li> <li>Wegovy (Novo Nordisk) in MASH, US</li> </ul>
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> <li>MASH, US</li> </ul>
SPECIAL TOPIX	<ul style="list-style-type: none"> <li>MASH Screening and Management among PCPs and Endocrinologists, US</li> </ul>

## Other Gastroenterology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"> <li>Celiac Disease, US</li> <li>Irritable Bowel Syndrome, US</li> <li>Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US (2025)</li> </ul>
LAUNCH DYNAMIX	<ul style="list-style-type: none"> <li>Iqirvo (Ipsen) in Primary Biliary Cholangitis, US</li> <li>Linerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, US</li> <li>Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US</li> </ul>
SPECIAL TOPIX	<ul style="list-style-type: none"> <li>The Business of Gastroenterology, US</li> </ul>

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
SPECIAL TOPIX	Current events on specific interest areas



# 2026 Rheumatology Publications

## Lupus

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Cutaneous Lupus, US (2026 refresh)</li> <li>• Systemic Lupus Erythematosus, US</li> <li>• Systemic Lupus Erythematosus Pipeline Refresh, US</li> <li>• Systemic Lupus Erythematosus, EU5</li> <li>• Lupus Nephritis, China</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Lupus Nephritis, US</li> <li>• Lupus Nephritis, EU5</li> <li>• Lupus Nephritis, Brazil</li> <li>• Lupus Nephritis, Canada</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Gazyva (Genentech) in Lupus Nephritis, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Lupus Nephritis, US</li> <li>• Systemic Lupus Erythematosus, US</li> <li>• Systemic Lupus Erythematosus &amp; Lupus Nephritis, EU5</li> <li>• Cutaneous Lupus, US</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Systemic Lupus Erythematosus &amp; Lupus Nephritis, US</li> </ul>

## Spondyloarthritis (AS, nr-AxSpA, and PsA)

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Ankylosing Spondylitis &amp; nr-AxSpA, US</li> <li>• Ankylosing Spondylitis &amp; nr-AxSpA, EU5 (2025)</li> <li>• Psoriatic Arthritis, EU5 (2025)</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Psoriatic Arthritis, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Bimzelx (UCB) in AS &amp; nr-AxSpA, US</li> <li>• Bimzelx (UCB) in Psoriatic Arthritis, US</li> <li>• Sotyktu (BMS) in Psoriatic Arthritis, US*</li> </ul>

## Other Rheumatology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Idiopathic Inflammatory Myopathies, US (2026 Refresh)</li> <li>• Rheumatoid Arthritis, US (2026 Refresh)</li> <li>• Rheumatoid Arthritis, EU5 (2025)</li> <li>• Sjogren's Disease, US (2025)</li> <li>• Sjogren's Disease, US (2026 Refresh)</li> <li>• Systemic Sclerosis, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Rinvoq (AbbVie) in Giant Cell Arteritis, US</li> <li>• Ianalumab (Novartis) in Sjogren's Disease, US*</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>• Systemic Sclerosis, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>• ILD in Rheumatology, US (2026 Refresh)</li> <li>• Cell Therapy in Rheumatology, US</li> <li>• Biologic Coordinators Across Rheumatology, US</li> </ul>

<b>Key</b>	<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
	<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
	<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
	<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
	<b>PATIENT VOICE DYNAMIX</b>	Independent service capturing patient journey insights
	<b>SPECIAL TOPIX</b>	Current events on specific interest areas

\*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



# 2026 Nephrology Publications

## Rare Disease

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Focal Segmental Glomerulosclerosis, US</li> <li>Membranous Nephropathy, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>IgA Nephropathy, US</li> <li>IgA Nephropathy, EU5</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Fabhalta (Novartis) in C3G, US</li> <li>Empaveli (Apellis) in C3G, US</li> <li>Fabhalta (Novartis) in IgAN, US</li> <li>Vanrafia (Novartis) in IgAN, US</li> <li>Voyxact (Otsuka) in IgAN, US</li> <li>Filspari (Traverse) in FSGS, US*</li> <li>Atacicept (Vera) in IgAN, US*</li> <li>Povetacicept (Alpine) in IgAN, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Focal Segmental Glomerulosclerosis, US</li> <li>IgA Nephropathy, US</li> <li>IgA Nephropathy, EU5</li> <li>IgA Nephropathy, JP</li> <li>IgA Nephropathy, China</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>IgA Nephropathy, US</li> </ul>

## Lupus Nephritis

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lupus Nephritis, US (2025)</li> <li>Lupus Nephritis, EU5 (2025)</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lupus Nephritis, US (2025)</li> </ul>

## CKD, Dialysis & Transplant

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Transplant/AMR, US</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Dialysis–Nephrologist, US</li> <li>Dialysis, Renal Dietitian/NP/PA, US</li> <li>Hyperkalemia, US (2025)</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Vafseo (Akebia) in Renal Anemia, US</li> <li>OLC (Unicycive) in Hyperphosphatemia, US*</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Chronic Kidney Disease, Non-Dialysis, Nephrologist, US</li> <li>Chronic Kidney Disease, Non-Dialysis, PCP, US</li> <li>Dialysis, US</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>Chronic Kidney Disease, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Feedback from ASN Kidney Week, US</li> </ul>

### Key

<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
<b>PATIENT VOICE DYNAMIX</b>	Independent service capturing patient journey insights
<b>SPECIAL TOPIX</b>	Current events on specific interest areas



## Alzheimer's Disease

- |                       |   |
|-----------------------|---|
| <b>MARKET DYNAMIX</b> | <ul style="list-style-type: none"> <li>Alzheimer's Disease, US</li> </ul> |
|-----------------------|---|

## Migraine

- |                         |  |
|-------------------------|--|
| <b>REALTIME DYNAMIX</b> | <ul style="list-style-type: none"> <li>Migraine (Neurologists &amp; PCPs), US</li> </ul> |
|-------------------------|--|

## Multiple Sclerosis

- |                       |  |
|-----------------------|--|
| <b>MARKET DYNAMIX</b> | <ul style="list-style-type: none"> <li>Multiple Sclerosis, US</li> </ul> |
|-----------------------|--|

- |                              |  |
|------------------------------|--|
| <b>PATIENT VOICE DYNAMIX</b> | <ul style="list-style-type: none"> <li>Multiple Sclerosis, US</li> </ul> |
|------------------------------|--|

- |                      |   |
|----------------------|---|
| <b>SPECIAL TOPIX</b> | <ul style="list-style-type: none"> <li>Post-ACTRIMS/ECTRIMS Coverage</li> </ul> |
|----------------------|---|

## Psychiatric Indications

- |                       |  |
|-----------------------|--|
| <b>MARKET DYNAMIX</b> | <ul style="list-style-type: none"> <li>Behavioral and Psychiatric Symptoms in Alzheimer's, US</li> <li>Depressive Mood Disorders, US</li> <li>Schizophrenia, US</li> </ul> |
|-----------------------|--|

## Generalized Myasthenia Gravis

- |                         |   |
|-------------------------|---|
| <b>REALTIME DYNAMIX</b> | <ul style="list-style-type: none"> <li>Generalized Myasthenia Gravis, US</li> <li>Generalized Myasthenia Gravis, EU5</li> </ul> |
|-------------------------|---|

- |                              |   |
|------------------------------|---|
| <b>PATIENT CHART DYNAMIX</b> | <ul style="list-style-type: none"> <li>Generalized Myasthenia Gravis, US</li> <li>Generalized Myasthenia Gravis, EU5</li> </ul> |
|------------------------------|---|

- |                              |   |
|------------------------------|---|
| <b>PATIENT VOICE DYNAMIX</b> | <ul style="list-style-type: none"> <li>Generalized Myasthenia Gravis, US</li> </ul> |
|------------------------------|---|

- |                       |   |
|-----------------------|---|
| <b>LAUNCH DYNAMIX</b> | <ul style="list-style-type: none"> <li>Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US</li> <li>Imaavy, (J&amp;J) Generalized Myasthenia Gravis (gMG), US</li> <li>Gefurulimab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US*</li> <li>Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*</li> </ul> |
|-----------------------|---|

## Other CNS Indications

- |                       |   |
|-----------------------|---|
| <b>MARKET DYNAMIX</b> | <ul style="list-style-type: none"> <li>Chronic Inflammatory Demyelinating Polyneuropathy, US</li> </ul> |
|-----------------------|---|

- |                      |   |
|----------------------|---|
| <b>SPECIAL TOPIX</b> | <ul style="list-style-type: none"> <li>Biologic Coordinators in Neurology</li> <li>Cell Therapy in Neurology Indications, US</li> </ul> |
|----------------------|---|

<b>Key</b>	<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
	<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
	<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
	<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
	<b>PATIENT VOICE DYNAMIX</b>	Independent service capturing patient journey insights
	<b>SPECIAL TOPIX</b>	Current events on specific interest areas



## Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX

- *Diabetic Macular Edema & AMD, US*

## Neovascular Age-Related Macular Degeneration

PATIENT CHART DYNAMIX

- *Age-Related Macular Degeneration, US*

## Other Ophthalmology Indications

MARKET DYNAMIX

- *Diabetic Retinopathy, US*
- *Geographic Atrophy, US (2025)*
- *Thyroid Eye Disease (TED), US (2025)*

SPECIAL TOPIX

- *Gene Therapies in Retina, US*

Key

- MARKET DYNAMIX *Yearly market overview of key indication*
- REALTIME DYNAMIX *Quarterly (US) or semi-annual (EU5) indication updates*
- LAUNCH DYNAMIX *Monthly benchmark of newly launched products*
- PATIENT CHART DYNAMIX *Yearly review of large-scale patient chart audits*
- PATIENT VOICE DYNAMIX *Independent service capturing patient journey insights*
- SPECIAL TOPIX *Current events on specific interest areas*



## Bleeding Disorders

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Hemophilia A &amp; B, US</li> <li>Hemophilia A &amp; B, EU5</li> <li>Von Willebrand Disease, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Qfitlia (Sanofi) in Hemophilia A &amp; B, US</li> <li>Hympavzi (Pfizer) in Hemophilia A &amp; B, US</li> <li>Alhemo (Novo Nordisk) in Hemophilia A &amp; B, US</li> <li>Mim8 (Novo Nordisk) in Hemophilia A, US*</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>People with Bleeding Disorders</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>People with Bleeding Disorders</li> </ul>

## Hemoglobinopathies

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Sickle Cell Disease, US</li> <li>Thalassemia, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Aqvesme (Agiros Pharmaceuticals) in Thalassemia, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Sickle Cell Disease, US</li> <li>Thalassemia, US</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>Sickle Cell Disease, US</li> </ul>

## Paroxysmal Nocturnal Hemoglobinuria

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Paroxysmal Nocturnal Hemoglobinuria, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Paroxysmal Nocturnal Hemoglobinuria, US</li> </ul>

## Other Benign Hematology Indications

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Warm Autoimmune Hemolytic Anemia (w-AIHA)</li> <li>Immune Thrombocytopenic Purpura (ITP)</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Nipocalimab (J&amp;J) in w-AIHA, US*</li> <li>Wayrilz (Sanofi) in ITP, US</li> </ul>

Key

<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
<b>PATIENT VOICE DYNAMIX</b>	Independent service capturing patient journey insights
<b>SPECIAL TOPIX</b>	Current events on specific interest areas



## Hematologic Oncology

### Acute Myeloid Leukemia

<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Komzifti (Kura) in Acute Myeloid Leukemia, US</li> <li>Revuforj (Syndax) in Acute Myeloid Leukemia, US</li> </ul>
<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Acute Myeloid Leukemia, US</li> </ul>

### B-Cell Malignancies

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>B-Cell Malignancies, US</li> <li>Large B-Cell Lymphoma, EU</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Large B-Cell Lymphoma, US</li> <li>Chronic Lymphocytic Leukemia, US</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>B-Cell Malignancies, US</li> </ul>

### Multiple Myeloma

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Multiple Myeloma, EU5</li> </ul>
<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>Multiple Myeloma, US</li> </ul>
<b>LAUNCH DYNAMIX</b>	<ul style="list-style-type: none"> <li>Lynozytic (Regeneron) in Multiple Myeloma, US</li> <li>Blenrep (GSK) in Multiple Myeloma, US</li> <li>Darzalex Faspro (J&amp;J) in High-Risk Smoldering Multiple Myeloma, US</li> </ul>
<b>PATIENT CHART DYNAMIX</b>	<ul style="list-style-type: none"> <li>Multiple Myeloma, US</li> </ul>
<b>PATIENT VOICE DYNAMIX</b>	<ul style="list-style-type: none"> <li>Multiple Myeloma, US</li> </ul>
<b>SPECIAL TOPIX</b>	<ul style="list-style-type: none"> <li>High-Risk Smoldering Multiple Myeloma, US</li> </ul>

### Myeloproliferative Neoplasms (MPN)

<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Myeloproliferative Neoplasms, US</li> </ul>
-----------------------	--

## Medical Oncology

### Solid Tumors

<b>REALTIME DYNAMIX</b>	<ul style="list-style-type: none"> <li>PD-1 Inhibition in Solid Tumors, US</li> </ul>
<b>MARKET DYNAMIX</b>	<ul style="list-style-type: none"> <li>Non-Small Cell Lung Cancer, US</li> </ul>

### Key

<b>MARKET DYNAMIX</b>	Yearly market overview of key indication
<b>REALTIME DYNAMIX</b>	Quarterly (US) or semi-annual (EU5) indication updates
<b>LAUNCH DYNAMIX</b>	Monthly benchmark of newly launched products
<b>PATIENT CHART DYNAMIX</b>	Yearly review of large-scale patient chart audits
<b>PATIENT VOICE DYNAMIX</b>	Independent service capturing patient journey insights
<b>SPECIAL TOPIX</b>	Current events on specific interest areas



## Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at  
[www.clientportal.spherixglobalinsights.com](http://www.clientportal.spherixglobalinsights.com)